Eupraxia shares move to Nasdaq Global Select
Eupraxia Pharmaceuticals upgrades to Nasdaq’s top market tier and schedules multiple New York investor conference appearances in September 2026.
Rhea-AI Filing Summary
Eupraxia Pharmaceuticals Inc. (EPRX) announced that its common shares have commenced trading on the Nasdaq Global Select Market, having transferred from the Nasdaq Capital Market, while continuing to trade on the Toronto Stock Exchange under the same ticker. No action is required by shareholders in connection with the transfer. Management stated that meeting Nasdaq’s highest market tier requirements reflects the company’s progress as it advances its clinical programs.
The company also plans to engage investors through several conferences in New York in September 2026, including events hosted by Cantor, H.C. Wainwright and Morgan Stanley, featuring fireside chats, company presentations and one-on-one meetings.
Positive
- Common shares began trading on the Nasdaq Global Select Market, Nasdaq’s highest market tier, which is reserved for companies meeting more stringent financial, liquidity and governance standards.
Negative
- None.
Key Figures
Market tier: Nasdaq Global Select Market
Cantor fireside chat date and time: September 11, 2026 at 9:45am
H.C. Wainwright presentation date and time: September 14, 2026 at 2:00pm
+2 more
5 metrics
Market tier
Nasdaq Global Select Market
New listing tier for Eupraxia common shares, previously on Nasdaq Capital Market
Cantor fireside chat date and time
September 11, 2026 at 9:45am
Scheduled Cantor Global Healthcare Conference fireside chat in New York
H.C. Wainwright presentation date and time
September 14, 2026 at 2:00pm
Scheduled company presentation at H.C. Wainwright 28th Annual Global Investment Conference
Morgan Stanley conference meeting dates
September 15–16, 2026
Scheduled one-on-one meetings at Morgan Stanley 24th Annual Global Healthcare Conference
Clinical stage of EP-104GI
Phase 1b/2 trial
RESOLVE trial for treatment of eosinophilic esophagitis (EoE)
Key Terms
Nasdaq Global Select Market, Diffusphere™, Phase 1b/2 trial, eosinophilic esophagitis (EoE), +1 more
5 terms
Nasdaq Global Select Market market
"common shares have commenced trading on the Nasdaq Global Select Market."
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
Diffusphere™ technical
"leveraging its proprietary Diffusphere™ technology designed to optimize local,"
Phase 1b/2 trial medical
"EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial,"
eosinophilic esophagitis (EoE) medical
"the RESOLVE trial, for the treatment of EoE."
A chronic allergic condition in which white blood cells called eosinophils build up in the esophagus, causing inflammation that can make swallowing difficult, trigger chest pain, and sometimes lead to food getting stuck. Think of the esophagus like a garden hose that becomes narrowed and irritated by sticky residue; treatment often requires ongoing medication, dietary changes, or procedures. Investors watch this condition because it creates steady demand for drugs, medical devices, and diagnostic services, and can drive regulatory reviews and reimbursement decisions.
extended-release products medical
"development of locally delivered, extended-release products that have the potential"
FAQ
What Nasdaq change did EPRX announce in this Form 6-K?
Eupraxia Pharmaceuticals’ common shares have commenced trading on the Nasdaq Global Select Market, transferring from the Nasdaq Capital Market, and will continue under the ticker symbol EPRX.
Does the Nasdaq Global Select Market transfer affect EPRX’s TSX listing?
No. Eupraxia stated that its listing on the Toronto Stock Exchange remains unchanged, and its common shares continue to trade there under the ticker EPRX.
Which investor conferences will EPRX participate in September 2026?
Eupraxia plans to participate in the Cantor Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference in New York.
When is Eupraxia’s Cantor Global Healthcare Conference fireside chat scheduled?
The fireside chat at the Cantor Global Healthcare Conference is scheduled for September 11, 2026 at 9:45am, with the company also holding one-on-one investor meetings at the event in New York.
What stage is Eupraxia’s EP-104GI program mentioned in the filing?
Eupraxia reported that EP-104GI is in a Phase 1b/2 trial, called the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE), using local injection into the esophageal wall.
AI-generated analysis. How Rhea-AI works. Not financial advice.
